Tema Etfs LLC Acquires Shares of 36,120 Guardant Health, Inc. (NASDAQ:GH)

Tema Etfs LLC bought a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,120 shares of the company's stock, valued at approximately $1,103,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sherbrooke Park Advisers LLC acquired a new position in shares of Guardant Health during the 4th quarter worth $248,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Guardant Health in the fourth quarter worth $61,000. Point72 Asset Management L.P. acquired a new position in Guardant Health during the fourth quarter worth $26,673,000. Point72 Hong Kong Ltd bought a new position in Guardant Health during the fourth quarter valued at about $189,000. Finally, Polar Asset Management Partners Inc. lifted its position in shares of Guardant Health by 1,902.2% in the fourth quarter. Polar Asset Management Partners Inc. now owns 454,500 shares of the company's stock worth $13,885,000 after buying an additional 431,800 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on GH. Guggenheim reissued a "buy" rating and set a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. The Goldman Sachs Group increased their price target on Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Canaccord Genuity Group lifted their price target on shares of Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Raymond James restated an "outperform" rating and issued a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Finally, UBS Group raised their target price on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Twenty-one equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Guardant Health currently has a consensus rating of "Buy" and a consensus price target of $52.32.

Insiders Place Their Bets

In related news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the transaction, the chief executive officer now owns 2,202,672 shares in the company, valued at $107,952,954.72. The trade was a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 107,248 shares of company stock valued at $5,254,000. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Stock Performance

Shares of NASDAQ:GH traded down $2.88 during trading on Wednesday, hitting $37.09. 2,182,867 shares of the stock were exchanged, compared to its average volume of 2,170,414. The company has a market capitalization of $4.60 billion, a price-to-earnings ratio of -10.42 and a beta of 1.49. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $52.92. The company's fifty day simple moving average is $43.74 and its 200-day simple moving average is $39.88.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same quarter in the previous year, the company earned ($0.46) earnings per share. The business's revenue was up 20.8% compared to the same quarter last year. On average, research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.